Substituted lysergamide

General structure of lysergamides.

Substituted lysergamides are amides of lysergic acid and are collectively known as lysergamides or ergoamides. ^{[1] [2]} They include a number of compounds with potent agonist and/or antagonist activity at various serotonin and dopamine receptors, such as lysergic acid diethylamide (LSD) and lysergic acid amide (LSA; ergine), among others. Lysergamides contain an embedded tryptamine structure, and as a result can produce similar, often psychedelic, effects to those of the true tryptamines. ^{[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]}

Use and effects

The dosages, potencies, durations, and effects of lysergamides have been reviewed by Alexander Shulgin. ^{[18] [19] [20] [21] [22]}

List of substituted lysergamides

Lysergamides, tabulated by structure

Structure	Name	CAS number	R1	R6	R2	R3	Other
	LSA / LAA	478-94-4	H	CH3	H	H	-
	DAM-57	4238-84-0	H	CH3	CH3	CH3	-
	Ergometrine (Ergonovine)	60-79-7	H	CH3	CH(CH3)CH2OH	H	-
	Ergotamine	113-15-5	H	CH3	--	C17H18N2O4	-
	Methergine	113-42-8	H	CH3	CH(CH2CH3)CH2OH	H	-
	Methysergide	361-37-5	CH3	CH3	CH(CH2CH3)CH2OH	H	-
	Amesergide	121588-75-8	CH(CH3)2	CH3	C6H11	H	-
	LY-215840	137328-52-0	CH(CH3)2	CH3	C5H8OH	H	-
	Cabergoline	81409-90-7	H	H2C=CH-CH2	CONHCH2CH3	CH2CH2CH2N(CH3)2	-
	LAE-32	478-99-9	H	CH3	CH2CH3	H	-
	LAiP		H	CH3	CH(CH3)2	H	-
	LAtB		H	CH3	C(CH3)3	H	-
	LAcB		H	CH3	(CH2)4	H	-
	Cepentil		H	CH3	(CH2)5	H	-
	LSB	137765-82-3	H	CH3	CH(CH3)CH2CH3	H	-
	LSP		H	CH3	CH(CH2CH3)CH2CH3	H	-
	DAL		H	CH3	H2C=CH-CH2	H2C=CH-CH2	-
	MIPLA	100768-08-9	H	CH3	CH(CH3)2	CH3	-
	EIPLA		H	CH3	CH(CH3)2	CH2CH3	-
	ECPLA		H	CH3	C3H5	CH2CH3	-
	ETFELA		H	CH3	CH2CF3	CH2CH3	-
	LAMPA	40158-98-3	H	CH3	CH2CH2CH3	CH3	-
	EPLA		H	CH2CH3	CH2CH2CH3	CH3	-
	LSD / LAD	50-37-3	H	CH3	CH2CH3	CH2CH3	-
	ETH-LAD	65527-62-0	H	CH2CH3	CH2CH3	CH2CH3	-
	PARGY-LAD		H	HC≡C−CH2	CH2CH3	CH2CH3	-
	AL-LAD	65527-61-9	H	H2C=CH-CH2	CH2CH3	CH2CH3	-
	PRO-LAD	65527-63-1	H	CH2CH2CH3	CH2CH3	CH2CH3	-
	IP-LAD		H	CH(CH3)2	CH2CH3	CH2CH3	-
	CYP-LAD [23]		H	C3H5	CH2CH3	CH2CH3	-
	BU-LAD	96930-87-9	H	CH2CH2CH2CH3	CH2CH3	CH2CH3	-
	FLUORETH-LAD [24]		H	CH2CH2F	CH2CH3	CH2CH3	-
	ALD-52	3270-02-8	COCH3	CH3	CH2CH3	CH2CH3	-
	1P-LSD	2349358-81-0	COCH2CH3	CH3	CH2CH3	CH2CH3	-
	1B-LSD	2349376-12-9	COCH2CH2CH3	CH3	CH2CH3	CH2CH3	-
	1V-LSD		CO(CH2)3CH3	CH3	CH2CH3	CH2CH3	-
	1H-LSD [25]		CO(CH2)4CH3	CH3	CH2CH3	CH2CH3	-
	1DD-LSD		CO(CH2)10CH3	CH3	CH2CH3	CH2CH3	-
	1cP-LSD [26]		COC3H5	CH3	CH2CH3	CH2CH3	-
	1D-LSD		COC4H5(CH3)2	CH3	CH2CH3	CH2CH3	-
	1T-LSD		COC4H3S	CH3	CH2CH3	CH2CH3	-
	1S-LSD		CO(CH2)2Si(CH3)3	CH3	CH2CH3	CH2CH3	-
	1P-AL-LAD		COCH2CH3	H2C=CH-CH2	CH2CH3	CH2CH3	-
	1cP-AL-LAD		COC3H5	H2C=CH-CH2	CH2CH3	CH2CH3	-
	1T-AL-LAD [27]		COC4H3S	H2C=CH-CH2	CH2CH3	CH2CH3	-
	1P-ETH-LAD		COCH2CH3	CH2CH3	CH2CH3	CH2CH3	-
	1P-MIPLA		COCH2CH3	CH3	CH(CH3)2	CH3	-
	MLD-41	4238-85-1	CH3	CH3	CH2CH3	CH2CH3	-
	LSM-775	4314-63-0	H	CH3	CH2CH2-O-CH2CH2		-
	LPD-824	2385-87-7	H	CH3	(CH2)4		-
	LSD-Pip	50485-23-9	H	CH3	(CH2)5		-
	LSD-Azapane		H	CH3	(CH2)6		-
	LSZ	470666-31-0	H	CH3	CH2(CHCH3)2CH2		-
	2-Bromo-LSD	478-84-2	H	CH3	CH2CH3	CH2CH3	2-Br
	1P-BOL-148		COCH2CH3	CH3	CH2CH3	CH2CH3	2-Br
	12-Methoxy-LSD [28]	50484-99-6	H	CH3	CH2CH3	CH2CH3	12-OMe
	13-Fluoro-LSD [29]		H	CH3	CH2CH3	CH2CH3	13-F
	14-Hydroxy-LSD [30]		H	CH3	CH2CH3	CH2CH3	14-OH

See also

• Ergoline
• Bromocriptine
• Descarboxylysergic acid
• Fumigaclavine C
• Hydergine
• Lisuride
• Pergolide

References

1. Jamieson CS, Misa J, Tang Y, Billingsley JM (2021-04-29). "Biosynthesis and synthetic biology of psychoactive natural products". Chemical Society Reviews. 50 (12): 6950–7008. doi:10.1039/D1CS00065A. ISSN   0306-0012. PMC   8217322 . PMID   33908526.
   "There are three main ergot alkaloid classes, clavines, ergoamides (lysergamides), and ergopeptides, with 3 belonging to the ergoamide class." 2.5 Lysergic acid and LSD, p. 6970
2. Wong G, Lim LR, Tan YQ, Go MK, Bell DJ, Freemont PS, et al. (2022-02-07). "Reconstituting the complete biosynthesis of D-lysergic acid in yeast". Nature Communications. 13 (1): 712. Bibcode:2022NatCo..13..712W. doi:10.1038/s41467-022-28386-6. ISSN   2041-1723. PMC   8821704 . PMID   35132076.
   "The ergot alkaloids are broadly classified into three groups—the clavines, ergoamides, and the ergopeptines, all of which are distinguished by the different modifications appended to the core ergoline structure." Results and discussion / Biosynthetic resolution of the ergot alkaloid pathway
3. Hofmann A (June 1959). "Psychotomimetic drugs; chemical and pharmacological aspects". Acta Physiologica et Pharmacologica Neerlandica. 8: 240–58. PMID   13852489.
4. USpatent 2997470,Pioch RP,"LYSERGIC ACID AMIDES",published 1956-03-05,issued 1961-08-22 
5. Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID   4032428.
6. Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE (March 1994). "Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives". Pharmacology, Biochemistry, and Behavior. 47 (3): 667–673. doi:10.1016/0091-3057(94)90172-4. PMID   8208787. S2CID   16490010.
7. Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–409. doi:10.1007/BF02245940. PMID   7568626. S2CID   21484356.
8. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (September 2002). "Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)". Journal of Medicinal Chemistry. 45 (19): 4344–4349. doi:10.1021/jm020153s. PMID   12213075.
9. Schiff PL (October 2006). "Ergot and its alkaloids". American Journal of Pharmaceutical Education. 70 (5): 98. doi:10.5688/aj700598 (inactive 2024-11-22). PMC   1637017 . PMID   17149427.
10. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008). "The pharmacology of lysergic acid diethylamide: a review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMC   6494066 . PMID   19040555.
11. Nichols DE (2017). Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43. doi:10.1007/7854_2017_475. ISBN   978-3-662-55878-2. PMID   28401524.
12. Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, et al. (September 2016). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)". Drug Testing and Analysis. 8 (9): 891–902. doi:10.1002/dta.1884. PMC   4829483 . PMID   26456305.
13. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "Return of the lysergamides. Part II: Analytical and behavioural characterization of N⁶ -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 9 (1): 38–50. doi:10.1002/dta.1985. PMC   5411264 . PMID   27265891.
14. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, et al. (October 2017). "Return of the lysergamides. Part III: Analytical characterization of N⁶ -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD)". Drug Testing and Analysis. 9 (10): 1641–1649. doi:10.1002/dta.2196. PMC   6230477 . PMID   28342178.
15. Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, et al. (February 2018). "Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)". Drug Testing and Analysis. 10 (2): 310–322. doi:10.1002/dta.2222. PMC   6230476 . PMID   28585392.
16. Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, et al. (August 2019). "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)". Drug Testing and Analysis. 11 (8): 1122–1133. doi:10.1002/dta.2613. PMC   6899222 . PMID   31083768.
17. Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5055-9. PMC   6848745 . PMID   30298278.
18. Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4 . Retrieved 1 February 2025.
19. Jacob P, Shulgin AT (1994). "Structure-activity relationships of the classic hallucinogens and their analogs" (PDF). NIDA Res Monogr. 146: 74–91. PMID   8742795.
20. Shulgin AT (1982). "Chemistry of Psychotomimetics". In Hoffmeister F, Stille G (eds.). Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Berlin: Springer Berlin Heidelberg. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN   978-3-642-67772-4. OCLC   8130916.
21. Alexander T. Shulgin (1980). "Hallucinogens". In Burger A, Wolf ME (eds.). Burger's Medicinal Chemistry. Vol. 3 (4 ed.). New York: Wiley. pp. 1109–1137. ISBN   978-0-471-01572-7. OCLC   219960627.
22. Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252.
23. Kruegel AC. Novel Ergolines and Methods of Treating Mood Disorders. Patent WO 2022/226408
24. WO 2022/008627,Grill M,"Improved Method for the Production of Lysergic Acid Diethylamide (LSD) and Novel Derivatives thereof." 
25. Brandt SD, Kavanagh PV, Gare S, Stratford A, Halberstadt AL. Analytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD). Drug Test Anal. 2024 Jul 4. doi : 10.1002/dta.3767 PMID   38965834
26. Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, et al. (June 2020). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)". Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. PMC   9191646 . PMID   32180350.
27. Okada Y, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, Kanamori T, et al. (June 2024). "Synthesis and analytical characterization of 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD)". Drug Testing and Analysis. doi:10.1002/dta.3747. PMID   38922764.
28. Usdin E, Efron DH. Psychotropic Drugs and Related Compounds. (1972) p 100 ASIN   B002X3CDIY
29. WO 2021/076572,Olson DE, et al.,"Ergoline-like compounds for promoting neural plasticity" 
30. Libânio Osório Marta RF (August 2019). "Metabolism of lysergic acid diethylamide (LSD): an update". Drug Metabolism Reviews. 51 (3): 378–387. doi:10.1080/03602532.2019.1638931. PMID   31266388.